The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Pregabalin for Treatment of Generalized Anxiety Disorder: A 4-Week, Multicenter, Double-blind, Placebo-Controlled Trial of Pregabalin and Alprazolam
Abstract
BACKGROUND: Pregabalin inhibits release of excess excitatory neurotransmitters, presumably by binding to the alpha2-delta subunit protein of widely distributed voltage-dependent calcium channels in the brain and spinal cord. OBJECTIVE: To assess the anxiolytic efficacy of pregabalin in patients with generalized anxiety disorder. DESIGN: Double-blind, placebo-controlled, active-comparator trial. Patients were randomized to 4 weeks of treatment with pregabalin, 300 mg/d (n = 91), 450 mg/d (n = 90), or 600 mg/d (n = 89); alprazolam, 1.5 mg/d (n = 93); or placebo (n = 91). SETTING: Psychiatry research and clinic settings. PATIENTS: Outpatients meeting the DSM-IV criteria for generalized anxiety disorder, with a baseline Hamilton Anxiety Rating Scale (HAM-A) total score of 20 or greater. MAIN OUTCOME MEASURES: Change from baseline to end point in total HAM-A score in the pregabalin and alprazolam groups compared with the placebo group. The end point response criterion was 50% or greater reduction in the HAM-A total score. RESULTS: Pregabalin and alprazolam produced a significantly greater reduction in mean +/- SE HAM-A total score at last-observation-carried-forward end point compared with placebo (-8.4 +/- 0.8): pregabalin, 300 mg (-12.2 +/- 0.8, P<.001), 450 mg (-11.0 +/- 0.8, P = .02), and 600 mg (-11.8 +/- 0.8, P = .002), and alprazolam (-10.9 +/- 0.8, P = .02). By week 1 and at last-observation-carried-forward end point, the 3 pregabalin groups and the alprazolam group had significantly (P<.01) improved HAM-A psychic anxiety symptoms compared with the placebo group. Compared with the placebo group, HAM-A somatic anxiety symptoms were also significantly (P<.02) improved by the 300- and 600-mg pregabalin groups, but not by the 450-mg pregabalin (week 1, P = .06; week 4, P = .32) and the alprazolam groups (week 1, P = .21; week 4, P = .15). Of the 5 treatment groups, the 300-mg pregabalin group was the only medication group that differed statistically in global improvement at treatment end point not only from the placebo group but also from the alprazolam group. CONCLUSION: Pregabalin was significantly more efficacious than placebo for the treatment of psychic and somatic symptoms of generalized anxiety disorder and was well tolerated by most study patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1990) · Choice Reviews Online · doi:10.5860/choice.27-3338 · Cited by 35,305
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
Applied Linear Statistical Models
Ziegel, E. R., Neter, J., Wasserman, W., & Kutner, M. (1992) · Technometrics · doi:10.2307/1269588 · Cited by 9,907
(1976) · Medical Entomology and Zoology · Cited by 8,899
Kupper, L. L., Hosmer, D. W., & Lemeshow, S. (1990) · Journal of the American Statistical Association · doi:10.2307/2290035 · Cited by 7,599
Applied Linear Statistical Models
(1997) · Technometrics · doi:10.1080/00401706.1997.10485141 · Cited by 7,185
Applied Linear Statistical Models.
Lorenz, F., Neter, J., Wasserman, W., & Kutner, M. H. (1986) · Journal of the American Statistical Association · doi:10.2307/2289108 · Cited by 5,565
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Cited by
Pharmacologic management of neuropathic pain: Evidence-based recommendations
Dworkin, R. H., O’Connor, A. B., Backonja, M., Farrar, J. T., Finnerup, N. B., Jensen, T. S., Kalso, E. A., Loeser, J. D., Miaskowski, C., Nurmikko, T. J., et al. (2007) · Pain · doi:10.1016/j.pain.2007.08.033 · Cited by 2,126
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“Benzodiazepines: Alprazolam [589-593], bromazepam”
InfluentialBandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Tiippana, E. M., Hamunen, K., Kontinen, V. K., & Kalso, E. (2007) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000261517.27532.80 · Cited by 532
Depression, anxiety and acute pain: links and management challenges
Michaelides, A., & Zis, P. (2019) · Postgraduate Medicine · doi:10.1080/00325481.2019.1663705 · Cited by 428
Ca2+ channel α2δ ligands: novel modulators of neurotransmission
Dooley, D. J., Taylor, C. P., Donevan, S., & Feltner, D. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.12.006 · Cited by 387
Self-citationPregabalin: Its Pharmacology and Use in Pain Management
Gajraj, N. M. (2007) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000287643.13410.5e · Cited by 343
Negative Effects of Antiepileptic Drugs on Mood in Patients with Epilepsy
Mula, M., & Sander, J. W. (2007) · Drug Safety · doi:10.2165/00002018-200730070-00001 · Cited by 306
Hartford, J., Kornstein, S., Liebowitz, M., Pigott, T., Russell, J., Detke, M., Walker, D., Ball, S., Dunayevich, E., Dinkel, J., et al. (2007) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32807fb1b2 · Cited by 286
Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis
Baldwin, D., Woods, R., Lawson, R., & Taylor, D. (2011) · BMJ · doi:10.1136/bmj.d1199 · Cited by 285
Stahl, S. M., Porreca, F., Taylor, C. P., Cheung, R., Thorpe, A. J., & Clair, A. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.04.001 · Cited by 277
Tassone, D. M., Boyce, E., Guyer, J., & Nuzum, D. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.01.013 · Cited by 275
Identifying HAM‐A cutoffs for mild, moderate, and severe generalized anxiety disorder
Matza, L. S., Morlock, R., Sexton, C., Malley, K., & Feltner, D. (2010) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.323 · Cited by 269
Self-citationAndrews, G., Bell, C., Boyce, P., Gale, C., Lampe, L., Marwat, O., Rapee, R., & Wilkins, G. (2018) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867418799453 · Cited by 243
Strawn, J. R., Geracioti, L., Rajdev, N., Clemenza, K., & Levine, A. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1491966 · Cited by 214
“Discontinuation rates in double-blind, placebo-controlled trials of pregabalin in the treatment of GAD have generally been lower than those observed for both benzodiazepines [79,83] and 75 mg/day venlafaxine [86].”
BackgroundDell’osso, B., & Lader, M. (2013) · European Psychiatry · doi:10.1016/j.eurpsy.2011.11.003 · Cited by 210
“condition [6,26,63,139,140,143] as well as studies using a comparator with established efficacy [57,61,63,88,142,144].”
MethodHoughton, L. A., Fell, C., Whorwell, P. J., Jones, I., Sudworth, D. P., & Gale, J. D. (2007) · Gut · doi:10.1136/gut.2006.110858 · Cited by 204
Mellman, T. A. (2008) · Sleep Medicine Clinics · doi:10.1016/j.jsmc.2008.01.010 · Cited by 204
Mellman, T. A. (2006) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2006.08.005 · Cited by 165
Carl, E., Witcraft, S. M., Kauffman, B. Y., Gillespie, E. M., Becker, E. S., Cuijpers, P., Van Ameringen, M., Smits, J. A. J., & Powers, M. B. (2020) · Cognitive Behaviour Therapy · doi:10.1080/16506073.2018.1560358 · Cited by 151
Anxiety disorders: a comprehensive review of pharmacotherapies
Hoffman, E. J., & Mathew, S. J. (2008) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20041 · Cited by 149
Bandelow, B., Chouinard, G., Bobes, J., Ahokas, A., Eggens, I., Liu, S., & Eriksson, H. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990423 · Cited by 142
Gomez, A. F., Barthel, A. L., & Hofmann, S. G. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1472767 · Cited by 125
Pharmacotherapy for anxiety and comorbid alcohol use disorders
Ipser, J. C., Wilson, D., Akindipe, T. O., Sager, C., & Stein, D. J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007505.pub2 · Cited by 93
Novel treatment approaches for refractory anxiety disorders
Pollack, M. H., Otto, M. W., Roy-Byrne, P. P., Coplan, J. D., Rothbaum, B. O., Simon, N. M., & Gorman, J. M. (2008) · Depression and Anxiety · doi:10.1002/da.20329 · Cited by 77
Self-citationHoertel, N., Le Strat, Y., Blanco, C., Lavaud, P., & Dubertret, C. (2012) · Depression and Anxiety · doi:10.1002/da.21937 · Cited by 61
Andrade, C. (2013) · Bipolar Disorders · doi:10.1111/bdi.12130 · Cited by 18
Advances in the management of treatment-resistant anxiety disorders
Lanouette, N. M., & Stein, M. B. (2010) · Focus · doi:10.1176/foc.8.4.foc501 · Cited by 15
Seo, H.-J., Song, H. R., Jeong, S., Kim, J.-B., Lee, M.-S., Kim, J.-M., Yim, H. W., & Jun, T.-Y. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.09.037 · Cited by 13
Metadata
- Authors
- Rickels, K., Pollack, M. H., Feltner, D. E., Lydiard, R. B., Zimbroff, D. L., Bielski, R. J., Tobias, K., Brock, J. D., Zornberg, G. L., & Pande, A. C.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2005-09-01
- Volume
- 62
- Issue
- 9
- Pages
- 1022
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2107373225
- Cited by
- 280
- References
- 48
- FWCI
- 31.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.